Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Day One Biopharmaceuticals, Inc. - Common Stock (NQ:DAWN)

12.93 +0.06 (+0.47%)
Streaming Delayed Price Updated: 9:57 AM EST, Mar 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 458,558
Open 12.66
Bid (Size) 12.89 (200)
Ask (Size) 12.97 (200)
Prev. Close 12.87
Today's Range 12.60 - 13.11
52wk Range 5.635 - 13.20
Shares Outstanding 73,572,633
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
DAWN Shares Rally On Buyout Speculation But Retail Warns A Deal Might Not Materialise ↗
On Stocktwits, retail sentiment around DAWN stock stayed within the ‘extremely bullish’ territory over the past 24 hours. 
Via Stocktwits
Topics Economy
Day One Biopharmaceuticals Inc (NASDAQ:DAWN) Reports Q4 Revenue Beat but Wider Loss, Shares Dip ↗
Via Chartmill

Performance

YTD
+46.1%
+46.1%
1 Month
+12.4%
+12.4%
3 Month
+55.6%
+55.6%
6 Month
+72.9%
+72.9%
1 Year
+50.3%
+50.3%

More News

Read More
News headline image
Day One Bio (DAWN) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit ↗
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
Keep an eye on the top gainers and losers in Monday's session. ↗
Via Chartmill
Gapping stocks in Monday's session ↗
Via Chartmill
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
Via Chartmill
News headline image
Day One Completes Acquisition of Mersana Therapeutics
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Mersana Therapeutics Stock Explodes Over 200% To Notch Best Day Ever As $285M Buyout Trumps Analyst Downgrades: Retail Cheers ‘Very Good Bargain’ ↗
Via Stocktwits
News headline image
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout ↗
Via Benzinga
News headline image
Mersana Catapults 200% On Day One Bio's Surprise Buyout ↗
Via Investor's Business Daily
News headline image
MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal ↗
Via Stocktwits
News headline image
Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
Day One Reports Third Quarter 2025 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Day One Biopharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Day One Biopharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Day One Biopharmaceuticals, Inc. - Common Stock trade on?
Day One Biopharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Day One Biopharmaceuticals, Inc. - Common Stock?
The ticker symbol for Day One Biopharmaceuticals, Inc. - Common Stock is DAWN on the Nasdaq Stock Market
What is the current price of Day One Biopharmaceuticals, Inc. - Common Stock?
The current price of Day One Biopharmaceuticals, Inc. - Common Stock is 12.93
When was Day One Biopharmaceuticals, Inc. - Common Stock last traded?
The last trade of Day One Biopharmaceuticals, Inc. - Common Stock was at 03/05/26 09:57 AM ET
What is the market capitalization of Day One Biopharmaceuticals, Inc. - Common Stock?
The market capitalization of Day One Biopharmaceuticals, Inc. - Common Stock is 951.29M
How many shares of Day One Biopharmaceuticals, Inc. - Common Stock are outstanding?
Day One Biopharmaceuticals, Inc. - Common Stock has 951M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.